JUST IN: @FDAOncology approved dostarlimab (PD-1 inh, GSK) w/carboplatin+paclitaxel, followed by single-agent dostarlimab, for dMMR/MSI-H metastatic endometrial cancer. Approval based on RUBY trial published in @NEJM 2023 https://t.co/QAkLNAnmWy @OncoAlert @OncBrothers (@DrChoueiri)

#ICYMI the July issue— A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies, by @CLachowiez et al. https://t.co/PDtssjLQyN @OHSUSOM #leuSM (@BCD_AACR)

Learn about new #BTKinhibitor options, antibodies, BCL2 inhibitors, & cellular therapy for #CLL treatment from @DrMDavids @AdamKittai @wwierda & Dr. Lamanna! This activity from #ASCO23 provides clear guidance & strategies for optimal treatment: https://t.co/YuFAL21ldw @PeerView (@CllSociety)

Venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed AML - @DrHKantarjian #cancer #leukemia #MDAndersoncancercenter #researchers #venetoclax #aml #oncology #drugs #oncodaily https://t.co/xblGnHD2vX (@oncodaily)

@MDAndersonNews #Leukemia researchers identify the use of venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed #AML | @BloodJournal https://t.co/J2sUGN9nVh #leusm (@DrHKantarjian)

Respectfully disagree, we have also quite some examples of huge PFS improvement with OS detriment. Detriment, not even no effect, but pernicious effect. Examples: PI3K inhibitors in CLL/FL, venetoclax in MM. Can't guarantee you're benefiting patients just because PFS is extended (@Ivaj960612)

➡️ Check out our latest paper 📃 just out in @BloodJournal analyzing the outcomes of patients with Newly Dx AML having Splicing Factor gene mutations 🧬and the impact of Venetoclax based regimens 💊 @ CDDiNardo @DrHKantarjian @garciamanero @sanamloghavi @MDAndersonNews #leusm https://t.co/zDVTSmk4ci (@jayastuMD)

Similar findings with Venetoclax in t 11:14 myeloma , amazing how fast the light chains drop! (@RenoHemonc)

From the July issue— A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies, by @CLachowiez et al. https://t.co/mwHChay9AJ @OHSUSOM #leuSM (@BCD_AACR)

Preclinical study with translational relevance in a difficult to eradicate GI cancer, from @jpshen_md @MDAndersonNews in @CR_AACR Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma https://t.co/d0gInQaiix (@Aiims1742)

#17ICML | @tobyeyre82 (@OUHospitals) discusses the results of a MAIC of venetoclax vs. pirtobrutinib for patients with R/R CLL previously treated with a covalent BTK inhibitor: 🎥 https://t.co/w2TCvto7Im @icmlugano #CLLsm #LeuSM #HemOnc (@VJHemOnc)

Great talk by @NitinJainMD on T-ALL ➡️ CAR-T cells being optimized with promising results ➡️ Rationale for inhibition of BCL-2 BCL-xl ➡️ LCK in 40% of T-ALL sensitive to dasatinib/ponatinib. Clinical trial at @MDAndersonNews with chemo-VEN-ponatinib #leusm #ALL @_MDEducation (@FadiHaddad_MD)

"True research begins AFTER #FDA approval of the drug" - @DrHKantarjian highlighted by @Daver_Leukemia A lot of work to be done after drugs are approved to optimize dosing & reduce the risk of AEs while maintaining efficacy, such as with #venetoclax #leusm (@FadiHaddad_MD)

Among take-homes of NADIM II study with perioperative #Immunotherapy and #Chemotherapy in stage III #NSCLC #lungcancer ➡️combination chemo regimen may matter for pCR ➡️carboplatin-paclitaxel my preferred option @OncoViews @OncoAlert @MARIANOPROVENCI https://t.co/2zh0qlVVAm (@gbanna74)

Promising results of Providence-sponsored trial from @davidbpage & colleagues published in @Nature_NPJ Breast Cancer. Trial evaluated pembrolizumab with either weekly paclitaxel or flat-dose capecitabine in treating patients w/ metastatic #TNBC. Details: https://t.co/hF3DFdWDax. (@ChilesResearch)

Phase I/II study of 1L carboplatin, nab-paclitaxel, pembrolizumab in NSCLC @OncJournal (n=46) from Drs. @ryangentzler @JPatelMD et al. RR 35%, mPFS 5.6m, mOS 15.4m with 3y OS rate 24%. No significant difference by PDL1 status noted. https://t.co/kGmFammmzE (@StephenVLiu)

New #JITC article: Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial https://t.co/0MlgE4Cb9b @KoheiShitara (@jitcancer)

Our @CULymphoma lead Dr. @mana1981 contributed to a multicenter study of venetoclax in relapsed mantle cell lymphoma, now published @BloodAdvances. #lymsm cc @YazeedSawalha @othman_salim @PallawiTorkaMD @BrianHill_MDPhD https://t.co/v47FuVAw0z (@CULymphoma)

#ICYMI— A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies, by @CLachowiez et al. https://t.co/QqtrVrDF4l @OHSUSOM #leuSM (@BCD_AACR)

WATCH: @BrunaPellini, of @MoffittNews, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced NSCLC treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel. #oncology https://t.co/xLqMUTcDto (@OncLive)

Ailawadhi et al report on safety, efficacy, #pharmacokinetics, and #pharmacodynamics of #lisaftoclax, a novel, selective BCL-2 inhibitor in patients with relapsed or refractory chronic #LymphocyticLeukemia and other hematologic malignancies. @DrMDavids (@CCR_AACR)

Debatable and not what patients told/tell us. My mother was recently on AML (Azacitadine/Venetoclax). I was keen for her to stop (Bone marrow CR) she wanted to remain on therapy. She was incredibly keen to stay on therapy. This study will start to address de-escalation IMO (@scserendipity1)

Key Paper in treatment of Older AML ➡️out in @AjHematology https://t.co/Wa9gO2kET0 Incorporation of venetoclax-based therapy & increased utilization of Allo SCT has led to higher rates of quality remissions & significant improvement in OS for patients aged > 60 years. @Tapkadia (@DrHKantarjian)

@Othman_Al_Sawaf berichtet, in welchen Punkten #Pirtobrutinib bei #rrCLL gegenüber #Venetoclax nicht unterlegen ist: https://t.co/TWJBmF82d1 #Hämatologie #EHA23 @UniCologne @TheCrick @uclcancer @SwantonLab (@MT_Onkologie)

A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies— by @CLachowiez et al. https://t.co/p3FEtJd5Jn @OHSUSOM #leuSM (@BCD_AACR)

Day 5 - a provocative study of low-dose decitabine weekly + weekly venetoclax in HR-MDS & AML #leusm #mdssm https://t.co/3xYbQKWamb (@Anand_88_Patel)

Excited to see our work published in Clinical Cancer Research on our metronomic, low dose decitabine+venetoclax in MDS and AML! https://t.co/X7CDh3dfmb Thank you to @MendelGoldfing1 @Amitvermamds @Saunthararajah for making this possible (@LavidDevitz)

Wie das Sechs-Jahres-Update der #CLL14-Studie den Stellenwert von #Venetoclax plus #Obinutuzumab bei #CLL untermauert, verrät @Othman_Al_Sawaf auf dem #EHA23. Das komplette Interview findet ihr auf https://t.co/QRjgnyBZRD #Hämatologie @UniCologne @TheCrick @uclcancer @SwantonLab (@MT_Onkologie)

New @ALLIANCE_org A222101 trial led by .@CathcartRake @MayoClinic tests safety, side effects & best dose of GM1 & if it works to reduce/prevent chemotherapy-induced peripheral #neuropathy in pts w/metastatic #breastcancer who receive treatment w/paclitaxel https://t.co/kWEVg6fLYm (@ALLIANCE_org)

Pleased to share @fredhutch results of #venetoclax and #ibrutinib in relapsed follicular lymphoma at #17ICML. #Zanubrutinib Rosewood study update also supports use of #BTK inhibitor in FL. @Rcl14L @mshadman @KatieLaiMD_MPH @DunleavyKieron #lymsm #17ICML (@UjjaniC)

Fixed-Duration Ibrutinib Plus Venetoclax Beneficial for Leukemia Overall response rates >95 percent, regardless of high-risk features; 36-month PFS 88 and 92 percent for those with, without high-risk features @Prasshmehta @DrPMPGI @IndianYoungOnco https://t.co/AR0XDDJqlo (@DeLionofPunjab)

Fixed-Duration Ibrutinib Plus Venetoclax Beneficial for Leukemia Overall response rates >95 percent, regardless of high-risk features; 36-month PFS 88 and 92 percent for those with, without high-risk features @Prasshmehta @DrPMPGI @IndianYoungOnco https://t.co/AR0XDDJYaW (@DeLionofPunjab)

First antiCD19 CART liso-cel results in r/r CLL (TRANSCEND CLL 004), presented by Dr Tanya Siddiqi CR/CRi in 18% in pts with r/r CLL after BTKi/venetoclax failure! High uMRD rates in both blood (63%) and marrow (59%) #17ICML (@Fer_martinmoro)

#EHA2023 | Daniela Cilloni: conferme per venetoclax anche in pazienti unfit alla chemioterapia nella leucemia mieloide acuta #AML @EHA_Hematology (@EmatoInfo)

CONGRESS|#17ICML @michaelwangmd, @MDAndersonNews summarizes the phase II WINDOW-2 trial results on chemo-free induction with ibrutinib-rituximab-venetoclax (IRV) followed by R-hyperCVAD/MTX in young pts with untreated MCL. IRV induced deep responses and was safe #lymsm #lymphoma (@lymphomahub)

AML with IDH mutation is more sensitive to venetoclax. Any possibility of performing BH3 profiling to see if Bcl2 dependent? (@MichaelodwyerMD)

A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies— by @CLachowiez et al. https://t.co/eCADNqPNTX @OHSUSOM #leuSM (@BCD_AACR)

Bobbie J. Rimel, MD, and Mansoor R. Mirza, MD, on Endometrial Cancer: Patient-Reported Outcomes With Dostarlimab, Carboplatin, and Paclitaxel https://t.co/PZuIMWsleN #gyncsm #endometrialcancer #oncolgy #ASCO23 @BJRimelMD @MirzaCPH @CedarsSinai @Rigshospitalet (@ASCOPost)

Interesting update on BCL2 inhibition in AML by Andrew Wei at #EHA2023 and in the review article in @Hemasphere_EHA : https://t.co/xvWr9nDfUy (@CoolsJn)

Important future question: Venetoclax or Pirtobrutinib after a covalent BTKi? #EHA2023 #CLL #venetoclax #pirtobrutinib (@tobyeyre82)

My #EHA2023 highlights: 1. ⁦@Othman_Al_Sawaf⁩ reporting the up date of the #CLL14 trial. Continued benefit for #venetoclax plus #obinutuzumab in 1L treatment of #CLL. (@HallekMichael)

Aza/Ven/Mag phase I/II in AML. My thinking; too toxic for HR MDS? Presentation by Naval Daver #EHA2023 (@KordastiL)